



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Osimertinib dimesylate

Cat. No.:	HY-79077
CAS No.:	2070014-82-1
Molecular Formula:	C <sub>30</sub> H <sub>41</sub> N <sub>7</sub> O <sub>8</sub> S <sub>2</sub>
Molecular Weight:	691.82
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (144.55 mM; Need ultrasonic)  
DMSO : 2.63 mg/mL (3.80 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.4455 mL	7.2273 mL	14.4546 mL
	5 mM		0.2891 mL	1.4455 mL	2.8909 mL
	10 mM		0.1445 mL	0.7227 mL	1.4455 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

Description	Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC <sub>50</sub> s of 12 and 1 nM against EGFR <sup>L858R</sup> and EGFR <sup>L858R/T790M</sup> , respectively.	
IC <sub>50</sub> & Target	EGFR <sup>L858R</sup> 12 nM (IC <sub>50</sub> )	EGFR <sup>L858R/T790M</sup> 1 nM (IC <sub>50</sub> )
In Vitro	Osimertinib (AZD-9291) shows similar potency to early generation tyrosine kinase inhibitor (TKIs) in inhibiting EGFR phosphorylation in EGFR cells harboring sensitising EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del), with mean IC <sub>50</sub> values ranging from 13 to 54 nM for Osimertinib (AZD-9291). Osimertinib (AZD-9291) also potently inhibits phosphorylation of EGFR in T790M mutant cell lines (H1975 (L858R/T790M), PC-9VanR (ex19del/T790M)), with mean IC <sub>50</sub> potency less than 15 nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	The tumor-bearing mice are treated with Osimertinib (AZD-9291) (5 mg/kg/day) for one to two weeks. Within days of treatment, 5 of 5 C/L858R mice displays nearly 80% reduction in tumor volume by magnetic resonance imaging MRI after therapy with Osimertinib (AZD-9291), while 5 of 5 mice treated with vehicle shows tumor growth <sup>[1]</sup> . Osimertinib (AZD-9291)	

demonstrates improved rat PK, reduced hERG affinity, and improved IGF1R margins relative to the previously described compounds, and so this compound is selected for further investigation. Osimertinib (AZD-9291) also offers an additional degree of broader chemical and profile diversity when compared to the previously described lead compounds. Upon dosing Osimertinib (AZD-9291) in three efficacy models, The comparable efficacy is observed at relatively low doses (10 mg/kg per day). The excellent efficacy is also observed when Osimertinib (AZD-9291) is dosed at 5 mg/kg per day<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Cell Assay <sup>[1]</sup>

PC-9 cells are seeded into T75 flasks (5×10<sup>5</sup> cells/flask) in RPMI growth media and incubated at 37°C, 5% CO<sub>2</sub>. The following day the media is replaced with media supplemented with a concentration of EGFR inhibitor equal to the EC<sub>50</sub> concentration predetermined in PC-9 cells. Media changes are carried out every 2-3 days and resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised and reseeded at the original seeding density in media containing twice the concentration of EGFR inhibitor. Dose escalations are continued until a final concentration of 1.5 μM ZD1839, 1.5 μM BIBW 2992, 1.5 μM WZ4002 or 160 nM Osimertinib (AZD-9291) are achieved<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration <sup>[1][2]</sup>

#### Mice<sup>[1]</sup>

The EGFR<sup>L858R</sup> and EGFR<sup>L858R+T790M</sup> mice (male and female) are used. Osimertinib (AZD-9291) is suspended in 1% Polysorbate 80 and administered via oral gavage once daily at the doses of 7.5 mg/kg and 5 mg/kg, respectively. Mice are imaged weekly at the Vanderbilt University Institute of Imaging Science. For immunoblot analysis, mice are treated for eight hours with drug as described before dissection and flash freezing of the lungs. Lungs are pulverized in liquid nitrogen before lysis.

#### Rats<sup>[2]</sup>

The male RccHan:WIST rats (10-week-old) are received a single oral dose of Osimertinib (AZD-9291) (200 mg/kg). Blood glucose levels are measured using an Accucheek Active meter.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Cancer Cell. 2020 Jan 13;37(1):104-122.e12.
- Cancer Discov. 2019 Jul;9(7):926-943.
- Nat Cancer. 2022 Apr;3(4):402-417.
- ACS Nano. 2022 Jul 21.
- Cell Rep Med. 2023 Jan 10;100911.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.

[2]. Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA